ALK and non-small cell lung carcinoma: At the last update in ASCO 2014 annual meeting, 343 pts with untreated advanced non-squamous ALK-positive NSCLC were treated with either crizotinib 250 mg PO BID (n = 172) or PPC (pemetrexed 500 mg/m2 + either cisplatin 75 mg/m2 or carboplatin AUC 5–6; all IV q3w for <=6 cycles; n = 171).